Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Rodig

Showing results (181-190 of 293) with videos related to

Pageof 30
Sort By:
The New England Journal of Medicine|August 31, 2012
MYD88 L265P somatic mutation in Waldenström's macroglobulinemiaSteven P Treon, Lian Xu, Guang Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeMargaretha G M Roemer, Ranjana H Advani, Azra H Ligon, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 15, 2023
Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone MarrowSam Sadigh, Daniel J DeAngelo, Jacqueline S Garcia, et al.
The Journal of Infectious Diseases|March 20, 2012
Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissueMathieu Angin, Douglas S Kwon, Hendrik Streeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2025
Phase II trial of cabozantinib in combination with nivolumab for advanced extrapancreatic neuroendocrine tumors (epNET)Kimberly J Perez, Nora Horick, Joanna Baginska, et al.
Haematologica|September 9, 2010
The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomasScott J Rodig, Jeffery L Kutok, Jennifer C Paterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.
British Journal of Haematology|April 26, 2014
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomideAndrew J Yee, Parameswaran Hari, Raffaella Marcheselli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 StudyRadhakrishnan Ramchandren, Eva Domingo-Domènech, Antonio Rueda, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Pageof 30

Showing results (181-190 of 293) with videos related to

Sort By:
Pageof 30
The New England Journal of Medicine|August 31, 2012
MYD88 L265P somatic mutation in Waldenström's macroglobulinemiaSteven P Treon, Lian Xu, Guang Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict OutcomeMargaretha G M Roemer, Ranjana H Advani, Azra H Ligon, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 15, 2023
Cutaneous Manifestations of Myeloid Neoplasms Exhibit Broad and Divergent Morphologic and Immunophenotypic Features but Share Ancestral Clonal Mutations With Bone MarrowSam Sadigh, Daniel J DeAngelo, Jacqueline S Garcia, et al.
The Journal of Infectious Diseases|March 20, 2012
Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissueMathieu Angin, Douglas S Kwon, Hendrik Streeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 20, 2025
Phase II trial of cabozantinib in combination with nivolumab for advanced extrapancreatic neuroendocrine tumors (epNET)Kimberly J Perez, Nora Horick, Joanna Baginska, et al.
Haematologica|September 9, 2010
The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomasScott J Rodig, Jeffery L Kutok, Jennifer C Paterson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2009
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALKAlice T Shaw, Beow Y Yeap, Mari Mino-Kenudson, et al.
British Journal of Haematology|April 26, 2014
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomideAndrew J Yee, Parameswaran Hari, Raffaella Marcheselli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 StudyRadhakrishnan Ramchandren, Eva Domingo-Domènech, Antonio Rueda, et al.
The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.
Pageof 30